Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2026

Summary of Basis in Diluted Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share, as adjusted to give effect to the reverse stock split for the three months ended March 31, 2026 and 2025 (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2026			2025
Numerator:
Net loss	$	(27,696	)	$	(10,860	)
Denominator:
Weighted-average common shares outstanding		10,931,593			3,437,671
Weighted-average shares used in computing basic and diluted net loss per share		10,931,593			3,437,671
Net loss per share attributable to common stockholders—basic and diluted	$	(2.53	)	$	(3.16	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Based on the amounts outstanding as of March 31, 2026 and 2025, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect, as adjusted to give effect to the reverse stock split:


	As of March 31,
	2026		2025
Options to purchase common stock		897,645		450,104
Common stock warrants		9,809,721		464
Total		10,707,366		450,568

Tempest Therapeutics, Inc. 10-Q